Pie Medical Imaging BV (PMI) announced today that they have signed an agreement with the Cardiovascular Research Foundation (CRF) to begin a close collaboration.
Pie Medical Imaging BV (PMI) announced today that they have signed an agreement with the Cardiovascular Research Foundation (CRF) to begin a close collaboration. Under this agreement the CRF Clinical Trials Center will use PMI’s solutions in their Angiographic Core Laboratory for clinical research and multi-center trials. As part of the agreement, CRF will also support further development of PMI’s new state-of-the-art products for analysis and visualization of medical images. The CRF Clinical Trials Center (CTC) plans and executes clinical investigations from first-in-man studies to large, multicenter, international trials and provides expert, independent qualitative and quantitative analyses of clinical and imaging data.
“We selected PMI for its well renowned software solutions for clinical trials and research in the areas of interventional cardiology, endovascular medicine and structural heart disease, as well as their ongoing and groundbreaking developments in the field of cardiovascular imaging solutions,” said Philippe Genereux, MD, Director of Angiographic Core Laboratory at the CRF Clinical Trials Center.
“PMI is pleased to work with CRF, a highly recognized international research and educational institution. Our collaboration with CRF gives PMI the opportunity to leverage CRF’s knowledge to further enhance our products and in ongoing development of new state-of-the-art solutions,” said Boudewijn Verstraelen, CEO at PMI.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.